San Diego, March 19, 2015 (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces the presentation of a poster at the 2015 American Academy of Dermatology’s Annual Meeting. The presentation entitled, “Melanoma gene expression in adhesive-tape sampled lesions is similar in primary tumors and patient derived xenografts.” further validates the ability of DermTech’s propriety Pigmented Lesion Assay to differentiate melanoma tissue from non-melanoma tissue. In addition, the study highlights the similarities in gene expression from melanoma samples collected using the company’s non-invasive Adhesive Skin Sample Collection Kit and surgical biopsy specimens. The company’s Pigmented Lesion Assay can be used to facilitate the clinical assessment of moles, or nevi, suspicious for melanoma, and reduce unnecessary surgical biopsy procedures.
John Alsobrook, Ph.D., the study’s lead author commented, “We are pleased to provide further evidence that the Pigmented Lesion Assay can accurately distinguish melanoma tissue from non-melanoma tissue and provide valuable information to physicians to facilitate the surgical biopsy decision.”
The presentation can be found at the company’s website, HERE. The Pigmented Lesion Assay has been tested and validated in multiple clinical studies involving more than 600 samples and over 200 melanomas.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected benefits of DermTech’s technology. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, and launching new products. These forward-looking statements speak only as of the date hereof and DermTech disclaims any obligation to update these statements.
DermTech is a commercial stage dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. For additional information visit: www.dermtech.com.
Steve Kemper, CPA, MBA, MS
Chief Financial Officer